1
Meeuwes, F. O., Brink, M., Van der Poel, M. W., Kersten, M. J., Wondergem, M. J., Mutsaers, P. G., Böhmer, L. H., Woei-A-Jin, F. J. S. H., Visser, O., Oostvogels, R., Jansen, P. M., Plattel, W. J., Huls, G. A., Vermaat, J. S., Nijland, M.
Veröffentlicht in: HemaSphere ; volume 6, page 1095-1096 ; ISSN 2572-9241;
2022
Veröffentlicht in: HemaSphere ; volume 6, page 1095-1096 ; ISSN 2572-9241;
2022
2
Cruijsen, M, van der Velden, W J F M, de Haan, A F J, Klein, S K, Hoogendoorn, M, Tromp, Y, de Valk, B, van Rees, B, de Boer, F, van der Spek, E, Pruijt, J, Verdonck, L F, Vellenga, E, Blijlevens, N, van de Loosdrecht, A A, Huls, G
Veröffentlicht in: Cruijsen , M , van der Velden , W J F M , de Haan , A F J , Klein , S K , Hoogendoorn , M , Tromp , Y , de Valk , B , van Rees , B , de Boer , F , van der Spek , E , Pruijt , J , Verdonck , L F , Vellenga , E , Blijlevens , N , van de Loosdrecht , A A & Huls , G 2020 , ' Use of azacitidine and its safety and efficacy in daily clinical practice in The Netherlands : the OCEAN study ' , Leukemia & Lymphoma , vol. 61 , no. 11 , pp. 2752-2755 . https://doi.org/10.1080/10428194.2020.1775217;
2020
Veröffentlicht in: Cruijsen , M , van der Velden , W J F M , de Haan , A F J , Klein , S K , Hoogendoorn , M , Tromp , Y , de Valk , B , van Rees , B , de Boer , F , van der Spek , E , Pruijt , J , Verdonck , L F , Vellenga , E , Blijlevens , N , van de Loosdrecht , A A & Huls , G 2020 , ' Use of azacitidine and its safety and efficacy in daily clinical practice in The Netherlands : the OCEAN study ' , Leukemia & Lymphoma , vol. 61 , no. 11 , pp. 2752-2755 . https://doi.org/10.1080/10428194.2020.1775217;
2020
3
Brink, M., Kahle, X.U., Vermaat, J.S.P., Zijlstra, J.M., Chamuleau, M., Kersten, M.J., Durmaz, M., Plattel, W.J., Lugtenburg, P.J., Stevens, W., Mous, R., de Vries, E.G.E., van der Poel, M.W.M., Panday, P.V.N., Huls, G., van Meerten, T., Nijland, M.
Veröffentlicht in: Brink , M , Kahle , X U , Vermaat , J S P , Zijlstra , J M , Chamuleau , M , Kersten , M J , Durmaz , M , Plattel , W J , Lugtenburg , P J , Stevens , W , Mous , R , de Vries , E G E , van der Poel , M W M , Panday , P V N , Huls , G , van Meerten , T & Nijland , M 2021 , ' Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study ' , Blood advances , vol. 5 , no. 15 , pp. 2958-2964 . https://doi.org/10.1182/bloodadvances.2021004295;
2021
Veröffentlicht in: Brink , M , Kahle , X U , Vermaat , J S P , Zijlstra , J M , Chamuleau , M , Kersten , M J , Durmaz , M , Plattel , W J , Lugtenburg , P J , Stevens , W , Mous , R , de Vries , E G E , van der Poel , M W M , Panday , P V N , Huls , G , van Meerten , T & Nijland , M 2021 , ' Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study ' , Blood advances , vol. 5 , no. 15 , pp. 2958-2964 . https://doi.org/10.1182/bloodadvances.2021004295;
2021